A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
Status:
Completed
Trial end date:
2013-02-21
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of
gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic
cough designed to evaluate the effectiveness of gefapixant in reducing daytime objective
cough frequency.